Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 6/20 | 0.40 |
| ▸ | NPC1 | O15118 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 6/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 4/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118274 | 0.83 | NPC1 (0.44) | KMT2AMAPTPOLBNPC1RAB9A | |
| SCHEMBL20118514 | 0.78 | SCN1A (0.37) | KMT2AMAPTPOLBPKMNPC1 | |
| SCHEMBL20118541 | 0.76 | SCN1A (0.39) | KMT2AMAPTPOLBPKMNPC1 | |
| SCHEMBL22364403 | 0.76 | KMT2A (0.42) | KMT2AKDM4EMAPTPOLBPKM | |
| SCHEMBL20118547 | 0.74 | LMNA (0.41) | KMT2AKDM4EPOLBPKMNPC1 | |
| SCHEMBL7062605 | 0.71 | PLAU (0.43) | KMT2AKDM4EMAPTPOLBPKM | |
| SCHEMBL9944382 | 0.70 | KMT2A (0.58) | KMT2AKDM4EMAPTPOLBPKM | |
| SCHEMBL30731163 | 0.70 | KMT2A (0.58) | KMT2AKDM4EMAPTPOLBPKM | |
| Hydrochloric Acid SCHEMBL30779160 | 0.68 | KMT2A (0.57) | KMT2AKDM4EMAPTPOLBPKM | |
| Hydrochloric Acid SCHEMBL29121031 | 0.68 | KMT2A (0.57) | KMT2AKDM4EMAPTPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3532057-B1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3532057-B1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-01 | — | — | US | disclosed |
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-01 | — | — | US | disclosed |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2018081513-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | KLKB1, SERPINB1, KLK1 | KMT2A 987/4885KDM4E 1137/4885MAPT 3099/4885 |
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | KMT2A 987/4885KDM4E 1137/4885MAPT 3099/4885 |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | KMT2A 987/4885KDM4E 1137/4885MAPT 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.